Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress
14 juin 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, June 14, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection
28 avr. 2017 18h30 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, April 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
29 mars 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, March 29, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Outlines Phase 3 Programme for Novel CDI Antibiotic Ridinilazole Following FDA and EMA Regulatory Meetings
01 févr. 2017 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress
15 déc. 2016 07h00 HE
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit’s Ridinilazole Preserves Microbiome During Treatment of C. Difficile Infection
20 juin 2016 12h30 HE
|
Summit Therapeutics PLC
Microbiome-Sparing Action of Ridinilazole associated with Superiority over Vancomycin in Sustained Clinical Response Rate OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Summit...
Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016
23 mai 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, May 23, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Paratek Presents Data from Omadacycline Clinical Development Program at ECCMID
11 avr. 2016 07h30 HE
|
Paratek Pharmaceuticals
Pooled analysis from Phase 2 and truncated Phase 3 studies demonstrates comparable safety and efficacy profiles for omadacycline compared with linezolid Single dose randomized trial...
Paratek Presents Pre-Clinical Data on the Effects of Omadacycline on Clostridium Difficile
11 avr. 2016 07h30 HE
|
Paratek Pharmaceuticals
AMSTERDAM, Netherlands, April 11, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today presented data from two pre-clinical studies evaluating the impact of omadacycline on...
Positive Results From Summit's Phase 2 CoDIFy Trial Highlight Potential of Ridinilazole in the Treatment of C. difficile Infection
11 avr. 2016 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, April 11, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...